Mallinckrodt Enrolls First Patient in Phase 2B Trial of H.P. Acthar® Gel (Repository Corticotropin Injection) for Amyotrophic Lateral Sclerosis (ALS)


Mallinckrodt’s PENNANT Trial to Assess Efficacy and Safety of H.P. Acthar Gel in ALS Patients
STAINES-UPON-THAMES, United Kingdom, June 14, 2017(STL.NEWS) — Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today conf…
http://bit.ly/2t3A4aH

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s